Hosted on MSN1mon
Viridian Therapeutics sees stock soar after Phase III TED success
Viridian Therapeutics’s stock has jumped after ... a bulging of eyes from the sockets. Steve Mahoney, Viridian’s president and CEO, said: “We are extremely pleased to announce better-than ...
pharmaphorum5mon
Viridian takes aim at Amgen's Tepezza with veligrotug data
Viridian said that the results of the phase ... its primary and secondary objectives and met what chief executive Steve Mahoney said were "high bars for both efficacy and safety," with a simpler ...
Morningstar1mon
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
“After a great year of execution across the portfolio, we enter 2025 poised to deliver on a number of important catalysts,” said Steve Mahoney ... About Viridian Therapeutics Viridian is ...
Yahoo Finance1mon
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
January 08, 2025--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ ... we enter 2025 poised to deliver on a number of important catalysts," said Steve Mahoney, Viridian’s President and CEO. "We ...